Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women

We showed that twenty weeks of SuperJump activity, an innovative workout training performed on an elastic minitrampoline, reduced bone resorption and increased bone formation in eumenorrheic women acting on the key points of the regulation of bone metabolism. The present study analyzed whether the g...

Full description

Bibliographic Details
Main Authors:	Sonya Vasto, Alessandra Amato, Patrizia Proia, Sara Baldassano
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Biology
Subjects:	biological mechanisms physical health sports and exercise physiology glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide
Online Access:	https://www.mdpi.com/2079-7737/11/2/296

Similar Items

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024-06-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023-12-01)

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
by: Akihiro Hamasaki, et al.
Published: (2024-06-01)

TGR5, GLP-1, and GIP expression in diabetic Wistar rats in response to Ficus exasperata vahl leaf extract
by: Olorunsola Israel Adeyomoye, et al.
Published: (2024-08-01)

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354
by: Tayla A. Rees, et al.
Published: (2024-10-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
by: Jang Won Son, et al.
Published: (2024-04-01)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
by: Giovanni Pacini, et al.
Published: (2022-05-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics
by: David Vogrinc, et al.
Published: (2024-10-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

Insulin sensitivity, islet cell function, and incretin axis in pregnant women with and without gestational diabetes mellitus
by: Niya Narayanan, et al.
Published: (2024-01-01)

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”
by: Tian-Yi Ren, et al.
Published: (2024-10-01)

Tirzepatide for type 2 diabetes
by: Sarah L Anderson, et al.
Published: (2023-08-01)

Maturity‐Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report
by: Mihiro Sue, et al.
Published: (2025-02-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
by: Alexandros Leonidas Liarakos, et al.
Published: (2023-07-01)

Does Incretin Agonism Have Sustainable Efficacy?
by: Sok-Ja Janket, et al.
Published: (2024-11-01)

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
by: Wael R. Sidrak, et al.
Published: (2024-11-01)

EXPRESSION OF INSULIN, GLUCAGON, SOMATOSTATIN, AND PANCREATIC POLYPEPTIDE IN THE PANCREAS OF THE EURASIAN MOORHEN (Gallinula chloropus)
by: Ahmed Abdellatif
Published: (2023-07-01)

The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Muhammad Umar Mahar, et al.
Published: (2024-12-01)

Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation
by: Joanna Goralska, et al.
Published: (2022-08-01)

Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent
by: ZHANG Lina, WANG Yan, ZHANG Kanghuai, LI Youjia
Published: (2023-05-01)

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
by: Duc Tin Tran, et al.
Published: (2024-11-01)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
by: Shangyu Chai, et al.
Published: (2023-08-01)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01)

Obesity is associated with impaired postprandial pancreatic polypeptide secretion
by: Yanyun Zhao, et al.
Published: (2023-06-01)

Entero-insular axis in children with simple obesity
by: Jerzy Starzyk, et al.
Published: (2009-06-01)

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
by: Antonio Ceriello, et al.
Published: (2023-10-01)

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
by: Eonju Jeon, et al.
Published: (2023-06-01)

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
by: Iona Davies, et al.
Published: (2025-02-01)

The VIP/VPAC1R Pathway Regulates Energy and Glucose Homeostasis by Modulating GLP-1, Glucagon, Leptin and PYY Levels in Mice
by: Daniel Sanford, et al.
Published: (2022-03-01)

Current State of Pharmacotherapy in Obesity
by: Won Jun Kim
Published: (2024-03-01)

Biotechnology Revolution Shaping the Future of Diabetes Management
by: Nilima Rajpal Kundnani, et al.
Published: (2024-12-01)